Sandoz Bolsters Respiratory Aspirations With Coalesce Acquisition
Addition Of UK-Based Drug Delivery Device Firm Adds To Complex Capabilities
Executive Summary
Sandoz is targeting growth opportunities in the respiratory complex generics space with the acquisition of UK-based drug delivery device firm Coalesce.
You may also be interested in...
Generics Bulletin Explains: Sandoz’s Spinoff From Novartis
Ahead of a Sandoz capital markets day on 8 June, Generics Bulletin explains what we know so far about the firm’s spinoff from parent company Novartis – as well as the questions that the companies are yet to answer.
Sandoz Adds To Anti-Infectives With Astellas Mycamine Deal
Sandoz and Astellas have struck a deal that will see the Novartis subsidiary acquire global rights to the Mycamine micafungin antifungal brand, bolstering Sandoz’s anti-infectives portfolio and hospital offering.
Sandoz Eyes In-House GLP-1 Development – Apart From ‘Key’ APIs
With glucagon-like peptide 1 products to treat diabetes and obesity continuing to gather pace, Sandoz has expressed confidence that it is capable of bring such complex products to market using its vast array of in-house capabilities.